Eisai reports upbeat results from PhIII epilepsy study

Two years after dumping its research program for perampanel as a possible new therapy for Parkinson's, Eisai says that it has reaped positive Phase III data for the drug in epilepsy. Researchers say that E2007 reduced median seizure frequency while increasing the percentage of patients who experienced a big drop in seizure frequency. Investigators said that they tracked a statistically significant response for patients taking both the 4 mg and 8 mg doses compared to placebo. Two more Phase III...

UT team tackles therapeutic Parkinson’s vaccine

Investigators engaged in preclinical studies have already seen how blocking a particular protein can reduce the level of nerve damage associated with Parkinson's disease. Now researchers at the University of Texas Health Science Center at Houston want to see if that same approach can be used to develop a therapeutic vaccine for the debilitating ailment....

Neuroscientist steers research into neurological disorders

Scientists at the Queensland Brain Institute have uncovered a vital clue into how the brain is wired, which could eventually steer research into nervous system disorders such as Parkinson's disease and cognitive disorders including...

Diet rich in omega-3 fatty acids linked to improved nervous-system function

The omega-3 essential fatty acids commonly found in fatty fish and algae help animals avoid sensory overload, according to research published by the American Psychological...

Asymmetrical arm swings while walking can be an early sign of Parkinson’s disease

Irregular arm swings while walking could be an early sign of Parkinson's disease, according to neurologists who believe early detection may help physicians apply treatments to slow further brain cell damage until strategies to slow disease progression are...